相关实验视频
Updated: Jan 12, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.4K
内异质性和免疫疗法耐药性:临床影响
B P Keenan1, M Yadav2, G Ansstas3
1Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, USA.
概括
瘤内异质性 (ITH) 驱动对癌症免疫疗法的耐药性,使瘤能够逃避免疫攻击. 了解ITH是开发克服治疗耐药性的新策略的关键.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 免疫疗法,特别是免疫检查点抑制剂,显示不完全的临床成功,需要对抗性机制的研究.
- 对免疫疗法的耐药性可以是天生的或获得的,在两者中都观察到共同的细胞和分子途径.
- 瘤与免疫微环境的相互作用驱动瘤的进化,并选择导致抗性的变体.
研究的目的:
- 审查将内异质性 (ITH) 与免疫疗法耐药性联系起来的证据.
- 探索ITH如何影响瘤适应和免疫逃避.
- 通过针对ITH,讨论克服免疫疗法耐药性的策略.
主要方法:
- 审查关于免疫疗法耐药性和ITH的现有文献.
- 对抗性背后的细胞和分子机制的分析.
- 讨论针对ITH的治疗方法.
主要成果:
- 由瘤与免疫共同进化形成的ITH,通过促进瘤适应和免疫逃避,有助于抵抗.
- 瘤内在的 ("硬件") 和瘤外在的 ("软件") 抵抗机制都受到ITH的影响.
- 目前在癌症管理中测量和利用ITH的方法有限.
结论:
- ITH是免疫疗法耐药性的关键因素,影响瘤进化和免疫逃避.
- 将ITH评估纳入临床实践对于设计有效的治疗策略至关重要.
- 未来的方法应侧重于针对ITH驱动的耐药性机制,包括免疫疗法组合和新型免疫调节标.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K

